MIMETAS Receives Funding For Kidney-On-A-Chip
News Sep 11, 2014
The organ-on-a-chip company MIMETAS has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. MIMETAS will collaborate in a consortium with Radboudumc (Nijmegen, The Netherlands) and FHNW (Basel, Switzerland). A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions has selected MIMETAS’ solution from a strong line-up of competing technologies.
The funding is awarded in the context of the NephroTube CRACK IT Challenge to support development of a microfluidic renal model, predicting renal toxicity during pre-clinical development. The consortium will use the funds to develop, analyze and validate a high-throughput kidney-on-a-chip model by combining MIMETAS’ OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™. The resulting model will be used to detect renal tubular injury observed in drug-induced nephrotoxicity. The model’s early prediction of nephrotoxicity will help to reduce animal experiments.